Feature | June 05, 2014

Siemens Announces First U.S. Installation of Symbia Intevo xSPECT System

June 5, 2014 — Fairview Health Services, Minneapolis, recently became the first U.S. healthcare facility to install the Symbia Intevo xSPECT system from Siemens Healthcare. The first ever xSPECT system, the Symbia Intevo fully integrates single-photon emission computed tomography (SPECT) and CT during image reconstruction, combining SPECT’s high sensitivity with the high specificity of CT and completely integrating data from the two modalities to generate high resolution and, for the first time, quantitative images.

“The Symbia Intevo’s ability to truly merge SPECT and CT data provides our physicians with invaluable additional diagnostic information, helping us to differentiate cancer from other forms of disease,” said Jerry Froelich, M.D., director of nuclear medicine and molecular imaging at the University of Minnesota. “For example, with the Intevo, we are better able to identify metastatic change within an area of degenerative change, such as the spine of older patients. The supporting information of the system’s xSPECT image enables us to make these kinds of objective interpretations of disease in cases where subjective interpretations had only been possible previously.”

The Symbia Intevo xSPECT system reconstructs both the SPECT and CT portions of the image into a much higher frame of reference than previous systems. The result is precise, accurate alignment of SPECT and CT that facilitates the extraction and deep integration of medically relevant information. This ability is also the basis for differentiating tissue boundaries in bone imaging. With xSPECT Bone, physicians can potentially provide additional support for detecting – and distinguishing between – cancerous lesions and degenerative disorders. In addition, single-step reading with integrated xSPECT Bone images may reduce physician time to read and report.

xSPECT Quant delivers precise alignment of SPECT and CT, providing physicians with essential volumetric information from the CT scan. This information enables accurate and consistent quantitative assessment – a numerical indication of a tumor’s level of metabolic activity. Accurate quantitative assessment enables the physician to assess whether a patient’s course of treatment has regressed, stabilized or grown.

The statements by Siemens customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption), there can be no guarantee that other customers will achieve the same results.

For more information: www.usa.siemens.com/healthcare

Related Content

GE Healthcare, molecular imaging, PET/CT, Discovery IQ, Discovery NM/CT 670 Pro, RSNA 2015

Discovery IQ PET/CT scanner image courtesy of GE Healthcare

News | Nuclear Imaging| November 16, 2015
GE Healthcare’s Molecular Imaging business will showcase the Discovery IQ positron emission tomography/computed...
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging| September 23, 2015
September 23, 2015 — New research de
Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production
News | Radiopharmaceuticals and Tracers| September 17, 2015
At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of...
PET, imaging agent, hidden blood clots, MGH, radiopharmaceutical probe, 64Cu-FBP8
News | Radiopharmaceuticals and Tracers| September 16, 2015
A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing...
Zevacor, IBA, 70 MeV cyclotron, Cyclone 70P, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| September 11, 2015
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon...
News | Radiopharmaceuticals and Tracers| September 11, 2015
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore...
NorthStar Medical Radioisotopes, approval, routine production, Molybdenum-99, Mo-99, University of Missouri Research Reactor, MURR
News | Radiopharmaceuticals and Tracers| August 31, 2015
NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Medraysintell, nuclear medicine, World Market Report, radiopharmaceuticals
News | Nuclear Imaging| July 06, 2015
Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June,...
nuclear medicine diagnostic market, North America, PET, SPECT, Mordor
News | Nuclear Imaging| June 29, 2015
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for...
Overlay Init